Loading organizations...
Whiz Partners Inc. is a Tokyo-based alternative asset management firm. It deploys Growth Equity and Global Macro Hedgefund strategies, focusing on Japan's healthcare, life science, and biotechnology sectors. Through investment partnerships like the Drug Discovery Gateway Investment Limited Partnership, Whiz Partners provides capital and support for innovation.
Established in 2010, the firm was founded by key figures such as Toshio Ando and President & CEO Tomoyuki Fujisawa. Their insight identified the need for targeted investment in specialized sectors. This commitment to Japan's healthcare ecosystem is exemplified by the 2018 launch of the Drug Discovery Gateway Investment Limited Partnership, fostering drug discovery.
Whiz Partners serves institutional investors, supporting companies within Japan's healthcare and life science landscape. Its vision is to cultivate a robust drug discovery and development environment nationwide. Providing strategic capital and expertise, the firm empowers enterprises creating advanced medical solutions, contributing to global health and economic progress.
Key people at WHIZ Partners.
Key people at WHIZ Partners.
WHIZ Partners has 1 tracked investment across 1 company. The latest tracked deal is $45.0M Series C in WHILL in September 2018.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 1, 2018 | WHILL | $45.0M Series C | Daiwa Securities Group, SBI Investment, Whiz Partners | 15th Rock Ventures, DG Incubation, Eight Roads Ventures, Innovation Network Corporation OF Japan, Mitsui Sumitomo Insurance Venture Capital, Mizuho Capital, Nippon Venture Capital |
